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Aims: Majority of previous studies of pegylated interferon α-2a (PegIFNα-2a) forced on naïve chronic hepatitis B
(CHB) patients, and the data of PegIFNα-2a in therapy of patients with prior exposure to nucleos(t)ide analogues is
rare. This study aimed to investigate the predictive role of serum quantitative hepatitis B surface antigen (HBsAg) in
predicting sustained response of PegIFNα-2a in HBeAg-positive CHB patients with prior lamivudine exposure.
Methods: Forty-six patients with prior lamivudine exposure received PegIFNα-2a for 12 months and followed-up
for 6 months. The clinical features of responders and non-responders were compared, and the predictive role of
quantitative HBsAg in predicting responders at the end of follow-up was evaluated. Responders were defined as an
ALT normalization, HBeAg seroconversion and sustained virological response at the end of follow-up.
Results: In this cohort, only 26.1% (12/46) patients were responders. The baseline characteristics of the responders
and non-responders were similar; however, the rates of ALT normalization, HBV DNA undetectability and HBeAg
seroconversion were all significantly higher in responders than that in non-responders. During the treatment and
follow-up, the HBsAg levels were all significantly lower in responders than that in non-responders. In predicting
reponders, the serum HBsAg cutoff of 6000 IU/mL at months 6 had a positive predictive value of 73.3 and a
negative predictive value of 96.8%, and with an area under the receiver operating characteristic curve of 0.869.
Conclusion: The responders toward PegIFNα-2a in CHB patients with prior lamivudine exposure is not high, and
serum HBsAg <6000 IU/Ml at months 6 of on-treatment had a high value to predict long-term outcomes of
treatment.
Keywords: Chronic hepatitis B, Lamivudine exposure, Pegylated interferon α-2a, Hepatitis B surface antigen
quantification, PredictabilityIntroduction
Hepatitis B virus (HBV) infection is a global public health
problem [1]. It is estimated that a significant proportion of
these patients will eventually die from complications (such
as cirrhosis, liver failure and hepatocellular carcinoma)
directly related to their chronic HBV infection, accounting
for one million deaths annually [1]. In the last decade,
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stated.great strides have been made in the treatment of adult
chronic hepatitis B (CHB) [2]. Though these oral NAs
treatments may eliminate the HBV virus from the blood,
they cannot clear intrahepatic covalently closed circular
DNA (cccDNA) from a chronically infected liver, and do
little to block the release of hepatitis B surface antigen
(HBsAg) into the blood. As a result, majority of them only
have a marginal effect on restoring the patients HBV
immune response, and there are several problems naturally
related to suboptimal response, viral resistance and the lack
of a sustained curative response.td. This is an Open Access article distributed under the terms of the Creative
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level has some relationship with intrahepatic cccDNA
[3], and serum HBsAg lower to an undetectable level
may indicate that intrahepatic cccDNA is eradicated at
all [4]. So currently, more and more scholars speculate
that the main cause for the lack of a sustained curative
response with existing oral NAs therapy may be that none
of them targets the elimination of HBsAg from the blood,
and therefor point that HBsAg quantitive measurement
should be used as a benchmark for the efficacy evaluation
of anti-viral treatment.
Besides NAs agents, interferon α (IFNα), especially its
pegylated form, also has been approved and widely used
in therapy of CHB in clinical practice [5]. And there are
many evidence suggest that IFNs have two mechanisms
of action: a direct antiviral effect achieved inhibiting the
synthesis of viral DNA and by activating antiviral enzymes,
and a second mechanism that increases the cellular
immune response against hepatocytes infected with HBV.
As compared to NAs, the advantages of IFNα therapy
include a limited treatment course and less development
of resistance, and even results in clinical cure, with HBsAg
loss or seroconversion in a few patients. However, there
are also a considerable proportion of patients responded
poorly to IFNα therapy, and there are higher to 50% of
hepatitis B e antigen (HBeAg) positive patients could not
achieve HBeAg seroconversion [6]. Unfortunately, the
exact molecular mechanism of this ineffectiveness of IFNα
is still unknown.
Currently, how to identify and use indicators to predict
treatment response has been widely concerned. In present
study, we will evaluate the effectiveness of quantification
of serum HBsAg in predicting the response of pegylated
interferon α-2a in HBeAg-positive CHB patients with
prior lamivudine exposure, and the findings of this study
would provide an important reference for helping CHB
patients achieve sustained curative response.
Patients and methods
Patients
HBeAg-positive chronic hepatitis B patients with prior
lamivudine exposure and received pegylated interferon
alfa-2a for recurring antiviral therapy were screened in
this study, all of them were followed up at the Digestion
Department of Chengdu Military General Hospital from
January 2007 to December 2012. The inclusion criteria
were as follows: adults (18–70 years), prior lamivudine
exposure for more than 1 years, positive HBeAg statue,
HBV DNA levels higher than 1.0×10^5 copies/mL, and
elevated serum alanine amino-transferase (ALT) value.
The exclusion criteria were as follows: ①co-infection
with other hepatitis virus or human immunodeficiency
virus; ②evidence of other causes of liver disease, such
as autoimmune hepatitis and primary biliary cirrhosis;③evidence of advanced liver diseases, such as decompen-
sated cirrhosis, severe hepatitis, and hepatic carcinoma;
④poor compliance or no availability of detailed laboratory
test results.
This study was carried out in accordance with the ethics
committee of Chengdu Military General Hospital and
informed consent was obtained from each participant.
Study design and definition
This is a prospective observational study, and all eligible
participants were administered pegylated interferon alfa-2a
(PegINFα-2a) (Roche Pharmaceuticals, Shanghai, China) at
a dose of 180 μg once a week by subcutaneous injection
for 12 months. Quantification of serum HBsAg was carried
out at baseline, months 3, 6 and at the end of treatment
(12 months), and the quantitative HBV DNA and liver
function was also assessed at each time-point.
According to the follow-up outcomes in this study,
patients were designated as either responders or nonre-
sponders. Responders were defined as an ALT normali-
zation, accompanying with HBeAg seroconversion at
the end of treatment and the presence of a sustained
virological response. Patients who did not achieve the
above-mentioned criteria were defined as NRs. And
sustained virological response was defined as undetectable
serum HBV DNA both at the end of therapy and 6-month
of follow-up.
Laboratory measurements
Liver function was studied using an automatic biochemical
analyzer(Olympus AU5400, Olympus Corporation, Tokyo,
Japan), serum HBV DNA was quantified by PCR assay
with a lower limit of detection of 1000 copies/mL (DA AN
GENE. Co., Ltd. Guangzhou, China), and serum HBsAg
was measured quantitatively by a Roche chemilumines-
cence assay (Basel, Switzerland).
Statistical analysis
Quantitative variables were expressed as mean and stand-
ard deviation. Categorical variables were presented as
counts and percentages. The comparisons of quantitative
variables were performed using T-test, and comparisons
of qualitative variables were performed using Chi-square
test or Fisher’s exact test as appropriate. The accuracy of
serum HBsAg to predict response was assessed using the
receiver operating characteristic (ROC) curve. All P-values




A total of 59 patients were screened in this study and only
46 CHB patients (32 men and 14 women) were included.
The other 13 patient were excluded because of poor
Table 2 Comparison of ALT, HBV DNA, HBeAg
seroconversion and HBsAg during treatment and
follow-up between the responders and nonresponders
Variables Rs NRs P-value
The number of patients 12 34
ALT normalization (n,%)
Months 3 5(41.7%) 15(44.1%) 1.0000
Months 6 8(66.7%) 21(61.7%) 1.0000
Months 12 10(83.3%) 26(76.5%) 1.0000
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ure less than 1 years(N=5), and HCV confection(N=2). Of
patients included in this study, 26.1% (12/46) patients
were responders and 73.9% (34/46) patients were non-
responders towards PegIFN α-2a 12-month treatment,
and their detailed demographic and clinical characteristics
were shown in Table 1. There were no significant differ-
ences between responders and non-responders before
PegIFN α-2a treatment when age, sex, baseline ALT level,
viral load, and HBsAg levels were compared.Six-month follow-up 12(100%) 24(70.6%) 0.0439
HBV DNA undetectability (n,%)
Months 3 6(50.0%) 12(35.3%) 0.4949
Months 6 10(83.3%) 16(47.1%) 0.0430
Months 12 12(100%) 20(58.8%) 0.0088
Six-month follow-up 12(100%) 19(55.9%) 0.0042
HBeAg seroconversion
Months 12 10(83.3%) 11(32.4%) 0.0055
Six-month follow-up 12(100%) 11(32.4%) <0.0001
HBsAg (log IU/mL)
Months 3 3.5±0.5 4.1±0.4 0.0001
Months 6 3.1±0.7 3.9±1.1 0.0235
Months 12 2.9±0.4 3.7±0.9 0.0049
Six-month follow-up 2.5±0.6 3.8±0.7 <0.0001The biochemical and virological changes between
responders and nonresponders
At the end of 12-month PegINFα-2a treatment, both
serum ALT and HBV DNA levels were lower than that
at baseline for all patients. The subgroup comparison of
serum ALT and HBV DNA levels between responders
and nonresponders during the treatment are presented
in Table 2. For responders, the ALT normalization rate
was 41.7% (5/12), 66.7% (8/12) and 83.3% (10/12) at
months 3, 6 and 12 respectively; and the HBV DNA
undetectability rate was 50.0% (6/12), 83.3% (10/12), and
100% (12/12) at months 3, 6 and 12 respectively. For
nonresponders, the ALT normalization rate was 44.1%
(15/34), 61.7% (21/34) and 76.5% (26/34) at months 3, 6
and 12 respectively; and the HBV DNA undetectability
rate was 35.3% (12/34), 47.1% (16/34), and 58.8% (20/34)
at months 3, 6 and 12 respectively. In this cohort, the
percentage of ALT normalization in responders was
similar to that in nonresponders from months 3 to months
12, but statistically significantly at 6-month follow-up
(100% versus 70.6%, P=0.0439). As compared to nonre-
sponders, the undetectability rate of serum HBV DNA
was significantly lower in responders since months 6 of
treatment. In respect to HBeAg seroconversion, we also
found that its rate either at months 12 of treatment
(83.3% vs 32.4%, P=0.0055)or 6-month follow-up (100% vs
32.4%, P<0.0001) was significantly higher in responders
than that in non-responders.Table 1 Baseline characteristics of the responders and
non-responders
Variables Responders Non-responders P-value
The number of patients (N,%) 12(26.1%) 34(73.9%)
Age (years) 33.8±4.6 35.7±5.8 0.3113
Male (N,%) 8(66.7%) 24(70.6%) 1.0000
Body mass index (kg/m2) 22.6±2.1 22.1±1.9 0.4496
ALT (U/L) 168.5±54.2 131.7±67.9 0.0976
HBV DNA (log copies/mL) 6.1±1.3 6.4±0.5 0.2588
HBsAg (log IU/mL) 4.2±0.5 4.4±0.7 0.3686
Duration of prior LAM
exposure (years)
1.5±0.6 1.7±0.5 0.2643Quantitative HBsAg change between responders and
non-responders
As Table 2 showed that the mean HBsAg concentrations
decreased consistently during treatment and remained
at low levels during the post-treatment follow-up in
responders. Conversely, HBsAg in nonresponders showed
a relatively slight decrease during treatment and post-
treatment follow-up. It was worth mentioning that there
were 1 patient in responders obtained HBsAg loss, but
anti-HBs statue was negative.The significance of HBsAg in predicting responders
at six-month follow-up
Among 15 patients with HBsAg levels < 6000 IU/mL
at months 6, 73.3% (11/15) were responders at the six-
month of follow-up; among 31 patients with HBsAg
levels ≥ 6000 IU/mL at months 6, 3.2% (1/31) were
responder at the six-month of follow-up; and the differ-
ence between them was statistic significantly (P<0.0001).
At months 6, the cutoff of 6000 IU/mL of HBsAg had a
positive predictive value (PPV) of 73.3% and a negative
predictive value (NPV) of 96.8% for predicting responders
at the six-month of follow-up after PegIFN α-2a treatment,
and the corresponding area under the ROC curve at
months 6 were 0.869.
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Lamivudine is the first anti-HBV agent approved in
China, and it has been used in therapy of CHB patients
for more than one decade. Thus, there are many CHB
patients who have been treated with lamivudine, but the
control of HBV DNA is not ideal because of the high
rate of HBV resistance. Considering different mechanisms
of anti-HBV and no cross-resistance to NAs, PegIFNα-2a
also has been applied for salvage therapy of patient with
resistance to lamivudine. Additionally, there was no data
showed the existence of resistance to NAs could decrease
the efficacy of interferon to HBV. In this study, though we
found that 12-month PegIFNα-2a treatment resulted
to 67.4% (31/46) undetectable HBV DNA, 78.3% (36/46)
ALT normalization, and higher to 50% (23/46) HBeAg sero-
conversion, the combined response (ALT normalization
combined with HBV DNA negativity and HBeAg serocon-
version) was just 26.1%. So the salvage therapy of PegIFNα-
2a for CHB patients with prior NAs exposure was not ideal,
and how to optimize the existing treatment strategies
and early predict long-term responses was necessary
and important for the management of CHB.
In past decade, many evidence indicated that the
intrahepatic cccDNA decreasing would be probably an
ideal prognostic variable in predicting long-term outcomes
of antiviral treatment [7], but it was still a research proced-
ure, dependent on a liver biopsy, and hardly available to
the practicing hepatologist. Though the use of quantitative
HBV DNA is well established in monitoring antiviral effect
of NAs and predicting long-term risk of hepatocellular
carcinoma, its value in reflecting the immune control
of HBV was extremely limited. Recently, quantification
of serum HBsAg in naïve CHB patients has been re-
commended as an alternative marker for monitoring
and evaluating efficacy of treatment [8-10]. And several
independent studies have shown that the decline of serum
HBsAg level during interferon treatment mimics that of
intrahepatic cccDNA, suggesting that a decline or loss of
serum HBsAg is correlated with a more effective immune
control of HBV [3,4]. Moreover, the quantification of serum
HBsAg has also been recommended as a useful index to
guide interferon individualized treatment [11].
As we know, current therapeutic agents cannot com-
pletely remove HBV from liver; and the goal of antiviral
treatment is just to slow down the progression of liver
disease to cirrhosis and hepatocellular carcinoma, with the
ultimate goal of improving survival. The HBsAg loss and
eventual seroconversion would signify the best outcome
possible for patients with CHB [9]. It has been reported
that quantitative serum HBsAg and HBeAg are strong pre-
dictors of sustained HBeAg seroconversion to PegIFNa-2b
in HBeAg-positive patients; and quantitative serum HBsAg
level at 3 months of treatment could be used for the early
prediction of a sustained response to PegIFN therapy inHBeAg-negative CHB patients [12]. In our study, among
12 responders with ALT normalization, HBV DNA nega-
tivity and HBeAg seroconversion, the serum HBsAg levels
decreased consistently during treatment and remained at
low levels during the post-treatment follow-up. Conversely,
serum HBsAg in non-responders just showed a relative
slight decrease during both treatment and post-treatment
follow-up. Thus our findings further suggested that moni-
toring of serum HBsAg levels may predict ideal responses
towards interferon treatment earlier. And this finding was
also consistent with the findings of other published reports
[5,12]. Additionally, we also found that the cutoff of
6000 IU/mL of serum HBsAg at months 6 had a PPV of
73.3% and an NPV of 96.8% for predicting combined
responses of ALT normalization, HBV DNA negativity and
HBeAg seroconversion.
In summary, the percentage of responders toward
PegIFNα-2a in CHB patients with prior lamivudine ex-
posure is not high; but the early decrease of serum
HBsAg (< 6000 IU/mL at months 6) could be used as a
predictor of sustained combined response. Due to the
limitation of relatively small sample size, longer follow-
up and larger sample size prospective trials should be
required to confirm our findings.
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